PhaseBio Pharmaceuticals Balance Sheet Health

Financial Health criteria checks 0/6

Insufficient data to determine the health of PhaseBio Pharmaceuticals

Key information

n/a

Debt to equity ratio

n/a

Debt

Interest coverage ratio	n/a
Cash	n/a
Equity	n/a
Total liabilities	n/a
Total assets	n/a

Recent financial health updates

Recent updates

PhaseBio Pharmaceuticals GAAP EPS of -$0.34 misses by $0.03, revenue of $0.21M misses by $0.29M

Aug 12

PhaseBio Pharmaceuticals (NASDAQ:PHAS) Has Debt But No Earnings; Should You Worry?

Aug 10

PhaseBio shares surge after inking exclusive license agreement for bentracimab

Jun 17

What Kind Of Shareholders Hold The Majority In PhaseBio Pharmaceuticals, Inc.'s (NASDAQ:PHAS) Shares?

Mar 04

If You Had Bought PhaseBio Pharmaceuticals' (NASDAQ:PHAS) Shares A Year Ago You Would Be Down 28%

Jan 08

PhaseBio Pharmaceuticals EPS misses by $0.15

Nov 12

Financial Position Analysis

Short Term Liabilities: Insufficient data to determine if PHAS.Q's short term assets cover its short term liabilities.

Long Term Liabilities: Insufficient data to determine if PHAS.Q's short term assets cover its long term liabilities.

Debt to Equity History and Analysis

Debt Level: Insufficient data to calculate PHAS.Q's net debt to equity ratio to determine if it is satisfactory.

Reducing Debt: Insufficient data to determine if PHAS.Q's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: Insufficient data to determine if PHAS.Q's debt is well covered by operating cash flow.

Interest Coverage: Insufficient data to determine if PHAS.Q's interest payments on its debt are well covered by EBIT.

PhaseBio Pharmaceuticals Balance Sheet Health

Financial Health criteria checks 0/6

Key information

Recent financial health updates

PhaseBio Pharmaceuticals, Inc. announced delayed annual 10-K filing

PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filing

PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filing

PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filing

PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filing

PhaseBio Pharmaceuticals's Securities to Be Delisted from Nasdaq

Recent updates

PhaseBio Pharmaceuticals, Inc. announced delayed annual 10-K filing

PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filing

PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filing

PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filing

Chiesi Farmaceutici S.p.A. completed the acquisition of all of the assets of PhaseBio Pharmaceuticals, Inc. primarily related to bentracimab.

PhaseBio Pharmaceuticals, Inc. Announces Executive Changes

PhaseBio Pharmaceuticals, Inc. Announces Resignation of John P. Sharp as Chief Financial Officer, Effective November 30, 2022

PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filing

Chiesi Farmaceutici S.p.A. entered into an agreement to acquire all of the assets of PhaseBio Pharmaceuticals, Inc. primarily related to bentracimab for $100 million.

PhaseBio Pharmaceuticals, Inc.(OTCPK:PHAS.Q) dropped from NASDAQ Composite Index

PhaseBio Pharmaceuticals's Securities to Be Delisted from Nasdaq

PhaseBio Pharmaceuticals, Inc. Filed for Bankruptcy

Price target increased to US$18.00

Consensus revenue estimates fall by 68%

PhaseBio Pharmaceuticals GAAP EPS of -$0.34 misses by $0.03, revenue of $0.21M misses by $0.29M

PhaseBio Pharmaceuticals, Inc. Regains Compliance

PhaseBio Pharmaceuticals Receives Non-Compliance Notices from Nasdaq

Consensus forecasts updated

Phasebio Pharmaceuticals, Inc. Announces Successful Pre-Bla Meeting with U.S. Fda for Bentracimab

Price target decreased to US$14.33

PhaseBio Pharmaceuticals, Inc., Annual General Meeting, May 19, 2022

PhaseBio Pharmaceuticals, Inc. Announces Positive Results from Phase 2B Trial for Bentracimab

PhaseBio Pharmaceuticals Announces Bentracimab Manufacturing Update

PhaseBio Pharmaceuticals, Inc. Announces Bentracimab Phase 2b Trial Data Accepted for Late Breaking Clinical Research Presentation at the 2022 American College of Cardiology (ACC.22) Annual Scientific Session

Phasebio Pharmaceuticals, Inc. Provides Pemziviptadil (Pb1046) Program Update

Price target increased to US$16.00

Independent Director exercised options to buy US$116k worth of stock.

Independent Director Peter Klein has left the company

Consensus forecasts updated

PhaseBio Pharmaceuticals, Inc. Achieves Enrollment Milestones Supporting Interim Analysis of REVERSE-IT Global Phase 3 Trial, Enabling Preparation of BLA Submission for Bentracimab for Reversal of Antiplatelet Effects of Ticagrelor

Phasebio Pharmaceuticals and SFJ Pharmaceuticals Announce Approval of Ind Application in China for Bentracimab

PhaseBio Pharmaceuticals (NASDAQ:PHAS) Has Debt But No Earnings; Should You Worry?

PhaseBio Pharmaceuticals, Inc.(NasdaqGM:PHAS) dropped from Russell 3000E Index

Consensus revenue estimates increase to US$4.07m

Price target decreased to US$12.75

PhaseBio shares surge after inking exclusive license agreement for bentracimab

Consensus EPS estimates increase to -US$2.31

Consensus revenue estimates fall to US$76.8k

Price target increased to US$15.00

PhaseBio Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $56 million.

Full year 2020 earnings released: US$3.39 loss per share (vs US$1.43 loss in FY 2019)

Phasebio Pharmaceuticals and Biovectra Enter into Supply Agreement to Support Development and Commercialization of Bentracimab

What Kind Of Shareholders Hold The Majority In PhaseBio Pharmaceuticals, Inc.'s (NASDAQ:PHAS) Shares?

New 90-day high: US$4.45

SFJ Pharmaceuticals and PhaseBio Pharmaceuticals, Inc. Expands Its Pivotal Phase 3 Reverse-It Trial for Its Lead Product Candidate Bentracimab into the European Union

If You Had Bought PhaseBio Pharmaceuticals' (NASDAQ:PHAS) Shares A Year Ago You Would Be Down 28%

Price target lowered to US$13.50

New 90-day high: US$4.44

New 90-day high: US$3.80

Analysts lower revenue estimates to US$296.0k

Analysts lower revenue estimates to US$375.0k

Earnings beat expectations, revenue disappoints

PhaseBio Pharmaceuticals EPS misses by $0.15

New 90-day low: US$3.10

Phasebio Pharmaceuticals, Inc. Doses First Patients in Canada as Part of the REVERSE-IT Global Phase 3 Trial of Bentracimab

PhaseBio Pharmaceuticals, Inc. Announces Receipt of Minutes of End-Of-Phase 1 Meeting with the FDA and Alignment on a Single, Non-Randomized Phase 3 Trial to Support BLA Submission for PB2452

PhaseBio Pharmaceuticals, Inc.(NasdaqGM:PHAS) dropped from S&P Global BMI Index

New 90-day low - US$3.22

New 90-day low - US$3.87

Analysts lower revenue estimates to US$542.0k

First half earnings released

Price target lowered to US$14.75

Financial Position Analysis

Debt to Equity History and Analysis

Balance Sheet

Discover healthy companies